X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 24.9 18.2 137.0% View Chart
P/BV x 6.1 3.9 155.0% View Chart
Dividend Yield % 3.3 1.6 208.1%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7202,484 69.3%   
Low Rs1,134918 123.5%   
Sales per share (Unadj.) Rs394.5142.3 277.4%  
Earnings per share (Unadj.) Rs101.841.9 243.0%  
Cash flow per share (Unadj.) Rs116.346.3 251.1%  
Dividends per share (Unadj.) Rs40.0010.00 400.0%  
Dividend yield (eoy) %2.80.6 476.8%  
Book value per share (Unadj.) Rs200.3161.5 124.0%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.612.0 30.2%   
Avg P/E ratio x14.040.6 34.5%  
P/CF ratio (eoy) x12.336.7 33.4%  
Price / Book Value ratio x7.110.5 67.7%  
Dividend payout %39.323.9 164.6%   
Avg Mkt Cap Rs m241,435451,525 53.5%   
No. of employees `00010.93.7 293.7%   
Total wages/salary Rs m8,5593,649 234.5%   
Avg. sales/employee Rs Th6,129.610,184.4 60.2%   
Avg. wages/employee Rs Th785.8984.1 79.8%   
Avg. net profit/employee Rs Th1,581.32,998.5 52.7%   
INCOME DATA
Net Sales Rs m66,76437,764 176.8%  
Other income Rs m2,156848 254.2%   
Total revenues Rs m68,92038,612 178.5%   
Gross profit Rs m27,20414,138 192.4%  
Depreciation Rs m2,4611,182 208.2%   
Interest Rs m1,85923 8,011.6%   
Profit before tax Rs m25,04113,781 181.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4142,662 240.9%   
Profit after tax Rs m17,22411,119 154.9%  
Gross profit margin %40.737.4 108.8%  
Effective tax rate %25.619.3 132.6%   
Net profit margin %25.829.4 87.6%  
BALANCE SHEET DATA
Current assets Rs m46,62230,947 150.7%   
Current liabilities Rs m32,8435,195 632.2%   
Net working cap to sales %20.668.2 30.3%  
Current ratio x1.46.0 23.8%  
Inventory Days Days74117 63.6%  
Debtors Days Days7985 92.8%  
Net fixed assets Rs m39,02917,027 229.2%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m31,40042,341 74.2%   
Net worth Rs m33,89042,877 79.0%   
Long term debt Rs m18,6375 396,527.7%   
Total assets Rs m90,13649,684 181.4%  
Interest coverage x14.5595.0 2.4%   
Debt to equity ratio x0.50 501,676.5%  
Sales to assets ratio x0.70.8 97.5%   
Return on assets %21.222.4 94.4%  
Return on equity %50.825.9 196.0%  
Return on capital %48.532.2 150.8%  
Exports to sales %43.385.3 50.8%   
Imports to sales %6.922.9 30.0%   
Exports (fob) Rs m28,93432,198 89.9%   
Imports (cif) Rs m4,5848,654 53.0%   
Fx inflow Rs m29,18532,270 90.4%   
Fx outflow Rs m6,0218,775 68.6%   
Net fx Rs m23,16523,496 98.6%   
CASH FLOW
From Operations Rs m27,13210,379 261.4%  
From Investments Rs m-7,014-4,135 169.6%  
From Financial Activity Rs m-14,352-6,241 229.9%  
Net Cashflow Rs m5,7673 174,742.4%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   GLENMARK PHARMA  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Energy Stocks Witness Buying(11:30 am)

After opening the day in green, Share markets in India witnessed volatile trading activity and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 22, 2017 01:01 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - MERCK LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS